CompletedPhase 3NCT02770625
Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
Studying Gaucher disease type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ISU Abxis Co., Ltd.
- Principal Investigator
- Amel El Beshlawy, Prof.Abou El Reesh Children's Hospital
- Intervention
- ISU302(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2011 – 2014
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02770625 on ClinicalTrials.govOther trials for Gaucher disease type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06818838A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher DiseaseLingyi Biotech Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE2NCT02843035Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGenzyme, a Sanofi Company